Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00713882
Other study ID # 0802009649
Secondary ID
Status Completed
Phase N/A
First received July 7, 2008
Last updated March 10, 2009
Start date April 2008
Est. completion date November 2008

Study information

Verified date March 2009
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The aims and objectives of this research are to identify chronic health conditions, psychological disease, quality of life issues, and patient preferences for survivorship care in patients who have survived aggressive lymphoma.

Subjects will be asked to participate in an oral interview with the primary investigator, either in-person or over the telephone. It is estimated that the survey will take about an hour.


Description:

Survival rates for both non-Hodgkin's (NHL) and Hodgkin's lymphoma (HL) have improved in recent years due to the development of better treatments. However, the diagnosis and treatment may leave a cancer survivor with long-term consequences. It is recognized that patients cured of HL have increased mortality due to long-term effects of treatment. The literature also suggests that patients cured of NHL suffer from long-term complications. These complications may include infertility, cardiovascular disease, pulmonary disease, secondary cancer, osteoporosis, fatigue, and psychological disease. Limitations of the current literature on lymphoma survivors include that the majority of studies are retrospective in nature, and therefore do not take into account other risk factors for development of chronic health conditions, such as tobacco use, exercise, family history, and specifics of the cancer treatment. In addition, few studies have attempted to explore the relationship between chronic health conditions, psychological distress, patient-physician communication, and quality of life (QOL) in lymphoma survivors.

The aims and objectives of this research are to identify chronic health conditions, psychological disease, QOL, and patient preferences for survivorship care. A prediction model will then be developed integrating demographic, clinical, and health behavior data with chronic health conditions to predict poor psychosocial outcomes.

Subjects will be asked to participate in an oral interview with the primary investigator. The survey consists of demographic information, employment and workplace information, the Charlson Comorbidity Index, the Qualify of Life-Cancer Survivor questionnaire, the PHQ-9 (a depression screening tool), the Impact of Events Scale (a post-traumatic stress disorders screen), the State-Trait Anxiety Index, the Holmes-Rahe Stress Scale, Brief Fatigue Inventory, Leisure Time, Exercise Questionnaire, as well as questions pertaining to patient-physician communication and preferences for follow-up care. There are a series of qualitative or open-ended questions at the end of the survey, designed to understand the experience of being a survivor of lymphoma. These responses will be audio-taped (with the consent of the participant) in order to capture the verbatim responses of the participants, which is necessary for analysis of qualitative data.

Data will be entered into a password-protected database maintained by the primary investigator. Quantitative analysis will be done in JMP®7 statistical software. Analysis will be via multiple regression, with quality of life as the primary outcome. Predictive variables will include demographics, treatment data, comorbidities, fatigue, exercise, workplace issues, depression, anxiety, and post-traumatic stress disorder. Each variable will also be analyzed in a univariate model. Qualitative questions will be analyzed separately using grounded theory, a form of analysis that can be used to generate new ideas. This will involve selective coding technique, grouping concepts into categories, which lead to themes between the categories.

There are few risks involved with this study. It is possible that subjects may experience psychological distress due to the sensitive nature of some of the questions. In this case, participants may stop the interview at any time and withdraw consent. However, it is anticipated that this is unlikely to occur. In the event that the investigator finds that a subject has screened positive for depression, post-traumatic stress disorder, or anxiety; the patient's primary care physician will be notified, as long as the patient gives consent. If the patient is found to be suicidal at the time of the interview, the interviewer will accompany the patient to the emergency room.

Benefits of this research are the improved understanding of long-term outcomes in lymphoma survivors and the identification of factors that predict for poor QOL, so that in the future, interventions can be made to improve QOL in this patient population.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- adults who have been treated for either aggressive lymphoma (Hodgkins lymphoma, diffuse large B-cell lymphoma, follicular grade III NHL, or others)

- are greater than 2 years from the time of last treatment

- no known active cancer

Exclusion Criteria:

- unable to participate in an interview in English

- indolent lymphoma (i.e. non-curable, including follicular grades 1-2 NHL)

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Locations

Country Name City State
United States Weill Cornell Medical College New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life cross-sectional (time of interview) No
See also
  Status Clinical Trial Phase
Terminated NCT02070393 - Breast-Sparing Proton Therapy for Hodgkin's Disease Phase 0
Completed NCT00764829 - Blood Samples to Evaluate Biomarkers of Donor Chimerism N/A
Terminated NCT01500161 - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Phase 2
Completed NCT00901225 - Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant Phase 2
Completed NCT02639559 - Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Phase 2
Completed NCT00697684 - Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant Phase 1
Completed NCT00802113 - Autologous and Allogeneic Transplant for Relapsed Lymphoma Phase 1/Phase 2
Completed NCT01951885 - Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Phase 3
Completed NCT00754286 - A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer N/A
Completed NCT00364676 - Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Phase 1
Completed NCT00571662 - Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Phase 2